Samsung Biologics Co., Ltd. – FDA 483, Jul 30, 2024
Samsung Biologics Co., Ltd. in Incheon, Republic of Korea, received a Form 483 citing significant deficiencies in its drug substance and drug product manufacturing. Observations included inadequate aseptic processing controls, poor investigation practices for deviations and environmental monitoring excursions, and insufficient data integrity controls for electronic systems. The firm also faces concerns regarding cleaning validation, high rates of laboratory system suitability test failures, and incomplete bioreactor validation.
ID · 6e40e6e0-81d7-4a42-b6e2-13cc55efe248
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.